SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001346302-20-000019
Filing Date
2020-04-24
Accepted
2020-04-24 16:04:48
Documents
6
Period of Report
2019-12-31
Effectiveness Date
2020-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2020proxystatement.htm DEF 14A 667066
2 image21.jpg GRAPHIC 124174
3 pauledicksignature1.jpg GRAPHIC 37016
4 proxycardback1.jpg GRAPHIC 74282
5 proxycardfront1.jpg GRAPHIC 178843
6 xerislpharmrgba061.jpg GRAPHIC 124174
  Complete submission text file 0001346302-20-000019.txt   1393153
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38536 | Film No.: 20814949
SIC: 2834 Pharmaceutical Preparations